Could a drug combo offer new hope for advanced liver cancer patients?
Disease control
Recruiting now
This study tests whether adding the immunotherapy drug atezolizumab to a standard targeted therapy (cabozantinib or lenvatinib) works better than the targeted therapy alone for people with advanced liver cancer that cannot be surgically removed. The trial enrolls 122 adults whose…
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC